Sequencing Agents to Treat Castration-Resistant Prostate Cancer

Publication
Article
Special ReportsGenitourinary Cancers
Volume 1
Issue 1

Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.

Leonard G. Gomella, MD, FACS, Chair and Professor, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer (CRPC).

Read more about immunotherapy for the treatment of CRPC > >

Articles in this issue
Patient-Centered Management of Metastatic Renal Cell Carcinoma
Patient-Centered Management of Metastatic Renal Cell Carcinoma
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Cancer
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Cancer
Treatment of Advanced Renal Cell Carcinoma
Treatment of Advanced Renal Cell Carcinoma
Treatment Pathways and Sequencing Strategies in CRPC
Treatment Pathways and Sequencing Strategies in CRPC
Therapeutic Strategies for Managing Bone Health in Prostate Cancer
Therapeutic Strategies for Managing Bone Health in Prostate Cancer
Immunotherapy in CRPC
Immunotherapy in CRPC
Factors in Choosing First-Line Targeted Therapy in RCC
Factors in Choosing First-Line Targeted Therapy in RCC
Immune Response in Patients with RCC
Immune Response in Patients with RCC
Frontline Treatment of Kidney Cancer With Pazopanib and Sunitinib
Frontline Treatment of Kidney Cancer With Pazopanib and Sunitinib
Sequencing Agents to Treat Castration-Resistant Prostate Cancer
Sequencing Agents to Treat Castration-Resistant Prostate Cancer
Recent Videos
Related Content
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

Jordyn Sava
November 21st 2024
Article

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Jordyn Sava
November 18th 2024
Article

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

Jordyn Sava
November 15th 2024
Article

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Read More